Pharmacovigilance in Portugal: Activity of the Central Pharmacovigilance Unit

被引:14
|
作者
Batel-Marques, Francisco [1 ,2 ]
Mendes, Diogo [1 ,2 ]
Alves, Carlos [1 ,2 ]
Penedones, Ana [1 ]
Dias, Patricia [1 ,3 ,4 ]
Martins, Angelina [1 ,3 ]
Santiago, Luiz Miguel [1 ,5 ]
Fontes-Ribeiro, Carlos [1 ,4 ]
Caramona, Margarida [1 ,2 ]
Macedo, Tice [1 ,4 ]
机构
[1] Ctr AIBILI Assoc Invest Biomed & Inovacao Luz & I, Unidade Farmacovigilancia, Coimbra, Portugal
[2] Univ Coimbra, Fac Farm, Coimbra, Portugal
[3] Ctr Hosp & Univ Coimbra, Coimbra, Portugal
[4] Univ Coimbra, Fac Med, Coimbra, Portugal
[5] Univ Beira Interior, Fac Ciencias Saude, Covilha, Portugal
来源
ACTA MEDICA PORTUGUESA | 2015年 / 28卷 / 02期
关键词
Adverse Drug Reaction Reporting Systems; Pharmacovigilance; Portugal; ADVERSE DRUG-REACTIONS; HOSPITALIZED-PATIENTS; IMPORTANT INFORMATION; CAUSALITY ASSESSMENT; AMBULATORY-CARE; SAFETY; EVENTS; NURSES; WITHDRAWALS; METAANALYSIS;
D O I
10.20344/amp.5717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The aim of this study was to characterize the spontaneous reports of adverse events that were received by the Central Portugal Regional Pharmacovigilance Unit. Material and Methods: Spontaneous reports received between 01/2001 and 12/2013 were considered. The annual reporting ratios were estimated. The cases were characterized according to their seriousness, previous description, causality assessment, origin and professional group of the reporter, type of adverse event and pharmacotherapeutic groups of the suspected drugs most frequently reported. Results: The Pharmacovigilance Unit received 2408 reports that contained 5749 adverse events. In 2013, the reporting rate was estimated at 171 reports per million inhabitants. Fifty-five percent of the reports were assessed as serious. Ninety percent of the cases were assessed as being at least possibly related with the suspected drug. The suspected drugs most frequently reported were anti-infectives for systemic use (n = 809, 33%). The most frequently reported adverse events were "Skin and subcutaneous tissue disorders" (n = 1139, 20%). There were 154 (6.4%) reports resulting in life-threatening situations and/or death, and 88 (3.6%) containing at least one adverse event assessed as serious, unknown and certain or probable. Discussion: The present results are in line with those found in other studies, namely the seriousness and type of the adverse events and the pharmacotherapeutic groups of the most frequently reported suspected drugs. Conclusion: In the last years, the Central Portugal Regional Pharmacovigilance Unit has registered a growth in the reporting rate in general, as well as an increase in the reporting of unknown and serious adverse drug reactions.
引用
下载
收藏
页码:222 / 232
页数:11
相关论文
共 50 条
  • [21] Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
    Paolo Baldo
    Sara Francescon
    Giulia Fornasier
    International Journal of Clinical Pharmacy, 2018, 40 : 748 - 753
  • [22] Estimation of Theoretical Cost Preventability Achievable with an Effective Pharmacovigilance Activity in a Pharmacovigilance Regional Centre in Italy
    Tuccori, M.
    Convertino, I.
    Sansone, A. Capogrosso
    Mantarro, S.
    Marino, A.
    Montagnani, S.
    Saporiti, A.
    Blandizzi, C.
    DRUG SAFETY, 2015, 38 (10) : 1033 - 1034
  • [23] Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
    Baldo, Paolo
    Francescon, Sara
    Fornasier, Giulia
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (04) : 748 - 753
  • [24] Looking back on 20 years of work at the Porto Pharmacovigilance Centre, Portugal
    Ferreira-da-Silva, Renato
    Ribeiro-Vaz, Ines
    Silva, Ana Marta
    Marques, Joana
    Polonia, Jorge Junqueira
    CADERNOS DE SAUDE PUBLICA, 2021, 37 (10):
  • [25] Validation Rules as a First Step for Data Quality: Pharmacovigilance Application in Portugal
    Costa, Barbara
    Figueiredo, Bruno
    Pinheiro, Vera
    CARING IS SHARING-EXPLOITING THE VALUE IN DATA FOR HEALTH AND INNOVATION-PROCEEDINGS OF MIE 2023, 2023, 302 : 382 - 383
  • [26] PHARMACOVIGILANCE AND PATIENT SAFETY - A PLEA FOR REGIONAL PHARMACOVIGILANCE CENTRES
    Bergman, U.
    Mejyr, S.
    Odar-Cederlof, I
    Hellden, A.
    Bradley, T.
    Sjolin-Forsberg, G.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 30 - 30
  • [27] Pharmacovigilance and clinical trials: Experience of a French pharmacovigilance department
    Brocvielle, H.
    Thomas, L.
    Le Louet, H.
    DRUG SAFETY, 2007, 30 (10) : 962 - 963
  • [28] Implementation of Pharmacovigilance Activity in a Mental Hygiene Department
    Die-Kacou, H.
    Yeo-Tenena, Y. J. M.
    Kamagate, M.
    Yavo, J. C.
    Soumahoro, S.
    Daubrey-Potey, T.
    Kakou, A.
    Balayssac, E.
    Yao, Y. P.
    Delafosse, R. C. J.
    DRUG SAFETY, 2009, 32 (10) : 945 - 945
  • [29] Pharmacovigilance of vaccines
    Autret-Leca, E
    Bensouda-Grimaldi, L
    Jonville-Béra, AP
    Beau-Salinas, F
    ARCHIVES DE PEDIATRIE, 2006, 13 (02): : 175 - 180
  • [30] Pharmacovigilance on olanzapine
    Lingeswaran, Anand
    Shetty, Harsha
    Lahon, Kigshuk
    Paramel, Amit
    Sharma, Gyaneshwar
    INDIAN JOURNAL OF PHARMACOLOGY, 2010, 42 (04) : 252 - U24